D
Darjus F. Tschaharganeh
Researcher at German Cancer Research Center
Publications - 47
Citations - 4523
Darjus F. Tschaharganeh is an academic researcher from German Cancer Research Center. The author has contributed to research in topics: Cancer research & Cancer. The author has an hindex of 24, co-authored 35 publications receiving 3407 citations. Previous affiliations of Darjus F. Tschaharganeh include University Hospital Heidelberg & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Non-Cell-Autonomous Tumor Suppression by p53
Amaia Lujambio,Leila Akkari,Janelle Simon,Janelle Simon,Janelle Simon,Danielle Grace,Danielle Grace,Darjus F. Tschaharganeh,Jessica E. Bolden,Jessica E. Bolden,Zhen Zhao,Zhen Zhao,Vishal Thapar,Vishal Thapar,Johanna A. Joyce,Valery Krizhanovsky,Valery Krizhanovsky,Scott W. Lowe,Scott W. Lowe,Scott W. Lowe +19 more
TL;DR: The p53 tumor suppressor can restrict malignant transformation by triggering cell-autonomous programs of cell-cycle arrest or apoptosis as discussed by the authors, and also promotes cellular senescence, a tumor-suppressive program that involves stable cellcycle arrest and secretion of factors that modify the tissue microenvironment.
Journal ArticleDOI
Inducible in vivo genome editing with CRISPR-Cas9
Lukas E. Dow,Lukas E. Dow,Jonathan Fisher,Kevin P. O’Rourke,Kevin P. O’Rourke,Ashlesha Muley,Edward R. Kastenhuber,Edward R. Kastenhuber,Geulah Livshits,Darjus F. Tschaharganeh,Nicholas D. Socci,Scott W. Lowe +11 more
TL;DR: It is shown that doxycycline-regulated Cas9 induction enables widespread gene disruption in multiple tissues and that limiting the duration of Cas9 expression or using a Cas9D10A (Cas9n) variant can regulate the frequency and size of target gene modifications, respectively.
Journal ArticleDOI
Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer
Lukas E. Dow,Kevin P. O’Rourke,Kevin P. O’Rourke,Janelle Simon,Darjus F. Tschaharganeh,Johan H. van Es,Hans Clevers,Scott W. Lowe +7 more
TL;DR: It is revealed that CRC cells can revert to functioning normal cells given appropriate signals and provide compelling in vivo validation of the Wnt pathway as a therapeutic target for treatment of CRC.
Journal ArticleDOI
Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling.
Susann Weissmueller,Susann Weissmueller,Eusebio Manchado,Michael Saborowski,John P. Morris,Elvin Wagenblast,Carrie A. Davis,Sung-Hwan Moon,Neil T. Pfister,Darjus F. Tschaharganeh,Thomas Kitzing,Daniela Aust,E K Markert,Jianmin Wu,Jianmin Wu,Sean M. Grimmond,Sean M. Grimmond,Christian Pilarsky,Carol Prives,Andrew V. Biankin,Andrew V. Biankin,Scott W. Lowe,Scott W. Lowe,Scott W. Lowe +23 more
TL;DR: It is shown that sustained expression of mutant p53 is required to maintain the prometastatic phenotype of a murine model of pancreatic cancer, a highly metastatic disease that frequently displays p53 mutations, and platelet-derived growth factor receptor b (PDGFRb) is implicated as a prognostic marker and possible target for attenuating metastasis in p53 mutant tumors.
Journal ArticleDOI
Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma.
Darjus F. Tschaharganeh,Xin Chen,Philipp Latzko,Mona Malz,Matthias M. Gaida,Klaus Felix,Sara Ladu,Stephan Singer,Federico Pinna,Norbert Gretz,Carsten Sticht,Maria Lauda Tomasi,Salvatore Delogu,Matthias Evert,Biao Fan,Silvia Ribback,Lijie Jiang,Stefania Brozzetti,Frank Bergmann,Frank Dombrowski,Peter Schirmacher,Diego F. Calvisi,Kai Breuhahn +22 more
TL;DR: The transcriptional regulator YAP up-regulates Jag-1 to activate Notch signaling in HCC cells and mouse hepatocytes, suggesting the use of YAP and Notch inhibitors as therapeutics for gastrointestinal cancer.